InvestorsHub Logo
Followers 165
Posts 3153
Boards Moderated 0
Alias Born 11/03/2014

Re: alphapuppy post# 348252

Sunday, 01/17/2021 2:10:31 PM

Sunday, January 17, 2021 2:10:31 PM

Post# of 720615
alphapuppy, I recently re-watched the YouTube video where you modeled the overall survival (OS) for the DCVax-L Phase III clinical trial, based on the 2017 blinded & blended interim data.

Thank you again for putting this together. Since this is based on 2017 data, what impact do you think an additional 3 years of data maturity will have on your estimated mOS of 26.1 months for the DCVax-L treatment group:


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News